Prevalence of High HDL Cholesterol and Its Associated Factors Among Tunisian Women of Childbearing Age: A Cross-Sectional Study

Fatma Ben Cherifa, Jalila El Ati, Radhouene Doggui, Myriam El Ati-Hellal, Pierre Traissac, Fatma Ben Cherifa, Jalila El Ati, Radhouene Doggui, Myriam El Ati-Hellal, Pierre Traissac

Abstract

The protective role of high high-density lipoprotein cholesterol (HDL-C) against cardiovascular risk has been questioned recently. Due to the increasing trend of cardiovascular diseases (CVD) in Tunisia, this study aimed to determine the prevalence of high HDL-C and its associated factors in Tunisian women of childbearing age. A cross-sectional survey was conducted among a subsample of 1689 women, aged 20 to 49 years, in the Great Tunis region. Data on socio-demographic and lifestyle factors were collected by a questionnaire. Overall adiposity was assessed by body mass index (BMI). All biological variables were assayed in blood samples coated with anticoagulant ethylene diamine tetra acetic acid (EDTA) by enzymatic methods. Stata software (2015) was used for data management and statistical analysis. High HDL-C values were recorded in 26.6% of selected women. After adjustment for all socio-demographic and lifestyle factors, age, hypertension, and smoking were negatively associated with high HDL-C levels, while family history of cancer was positively associated with high HDL-C in women. An additional investigation on the relationship between high HDL-C and cancer risk should be performed due to controversial results.

Trial registration: ClinicalTrials.gov NCT01844349.

Keywords: Tunisian women of childbearing age; high HDL-C; prevalence; risk factors.

Conflict of interest statement

The authors declare that they do not have any conflict of interest.

Figures

Figure 1
Figure 1
Adjusted odds ratio (OR; 95% CI) of high HDL-C for age (education level, marital status, professional activity, household economic level, household size, and living area), lifestyle (self-reported practice of regular physical activity and smoking), and biological factors (hypertension status, diabetes status, family history of cancer, and family history of cardiovascular diseases).

References

    1. WHO . Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020. World Health Organization; Geneva, Switzerland: 2013.
    1. NIS . National Statistics on the Causes of Death in Tunisia 2015 and 2017. National Institute of Statistics; Tunis, Tunisia: 2020. (In French)
    1. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., Jacobs D.R., Jr., Bangdiwala S., Tyroler H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15. doi: 10.1161/01.CIR.79.1.8.
    1. The Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000. doi: 10.1001/jama.2009.1619.
    1. Assmann G., Gotto A.M., Jr. HDL cholesterol and protective factors in atherosclerosis. Circulation. 2004;109:III8–III14. doi: 10.1161/01.CIR.0000131512.50667.46.
    1. Marz W., Kleber M.E., Scharnagl H., Speer T., Zewinger S., Ritsch A., Parhofer K.G., von Eckardstein A., Landmesser U., Laufs U. HDL cholesterol: Reappraisal of its clinical relevance. Clin. Res. Cardiol. 2017;106:663–675. doi: 10.1007/s00392-017-1106-1.
    1. Marz W., Kleber M.E., Scharnagl H., Speer T., Zewinger S., Ritsch A., Parhofer K.G., von Eckardstein A., Landmesser U., Laufs U. Clinical importance of HDL cholesterol. Herz. 2017;42:58–66. doi: 10.1007/s00059-016-4499-0.
    1. Brites F., Martin M., Guillas I., Kontush A. Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit. BBA Clin. 2017;8:66–77. doi: 10.1016/j.bbacli.2017.07.002.
    1. Tosheska Trajkovska K., Topuzovska S. High-density lipoprotein metabolism and reverse cholesterol transport: Strategies for raising HDL cholesterol. Anatol. J. Cardiol. 2017;18:149–154. doi: 10.14744/AnatolJCardiol.2017.7608.
    1. Estrada-Luna D., Ortiz-Rodriguez M.A., Medina-Briseno L., Carreon-Torres E., Izquierdo-Vega J.A., Sharma A., Cancino-Diaz J.C., Perez-Mendez O., Belefant-Miller H., Betanzos-Cabrera G. Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease. Molecules. 2018;23:2730. doi: 10.3390/molecules23112730.
    1. Talbot D., Delaney J.A.C., Sandfort V., Herrington D.M., McClelland R.L. Importance of the lipid-related pathways in the association between statins, mortality, and cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis. Pharmacoepidemiol. Drug Saf. 2018;27:365–372. doi: 10.1002/pds.4393.
    1. Singh K., Rohatgi A. Examining the paradox of high high-density lipoprotein and elevated cardiovascular risk. J. Thorac. Dis. 2018;10:109–112. doi: 10.21037/jtd.2017.12.97.
    1. Oh I.H., Hur J.K., Ryoo J.H., Jung J.Y., Park S.K., Yang H.J., Choi J.M., Jung K.W., Won Y.J., Oh C.M. Very high high-density lipoprotein cholesterol is associated with increased all-cause mortality in South Koreans. Atherosclerosis. 2019;283:43–51. doi: 10.1016/j.atherosclerosis.2019.01.035.
    1. Madsen C.M., Varbo A., Nordestgaard B.G. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: Two prospective cohort studies. Eur. Heart J. 2017;38:2478–2486. doi: 10.1093/eurheartj/ehx163.
    1. El Ati J., Traissac P., Delpeuch F., Aounallah-Skhiri H., Beji C., Eymard-Duvernay S., Bougatef S., Kolsteren P., Maire B., Ben Romdhane H. Gender obesity inequities are huge but differ greatly according to environment and socio-economics in a North African setting: A national cross-sectional study in Tunisia. PLoS ONE. 2012;7:e48153. doi: 10.1371/journal.pone.0048153.
    1. WHO . Physical Status: The Use and Interpretation of Anthropometry. World Health Organization; Geneva, Switzerland: 1995.
    1. International Society of Hypertension Writing Group International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens. 2003;21:1983–1992. doi: 10.1097/00004872-200311000-00002.
    1. Gavin J.R., III, Albert K.G.M.M., Davidson M.B., DeFronzo R.A. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–1197. doi: 10.2337/diacare.20.7.1183.
    1. National Cholesterol Education Programs (US) Treatment of High Blood Cholesterol in, A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421. doi: 10.1161/circ.106.25.3143.
    1. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome—A new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469–480. doi: 10.1111/j.1464-5491.2006.01858.x.
    1. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet. 2001;358:2026–2033. doi: 10.1016/S0140-6736(01)07098-2.
    1. Lavie C.J., Milani R.V., Ventura H.O. Obesity and cardiovascular disease: Risk factor, paradox, and impact of weight loss. J Am. Coll. Cardiol. 2009;53:1925–1932. doi: 10.1016/j.jacc.2008.12.068.
    1. Epidata . EpiData Data Entry, Data Management and Basic Statistical Analysis System. Epidata Association; Odense, Denmark: 2008.
    1. StataCorp . Stata Statistical Software: Release 14.0. StataCorp LP; College Station, TX, USA: 2015.
    1. Hadj-Taieb S., Elasmi M., Hammami M.B., Marrakchi R., Amani K., Omar S., Sanhaji H., Jemaa R., Feki M., Kaabachi N. Dyslipidemia in the Greater Tunis population: Prevalence and determinants. Clin. Lab. 2012;58:763–770. doi: 10.7754/Clin.Lab.2011.110825.
    1. Soyama Y., Miura K., Morikawa Y., Nishijo M., Nakanishi Y., Naruse Y., Kagamimori S., Nakagawa H., Oyabe S. High-density lipoprotein cholesterol and risk of stroke in Japanese men and women: The Oyabe Study. Stroke. 2003;34:863–868. doi: 10.1161/01.STR.0000060869.34009.38.
    1. Kim S.M., Han J.H., Park H.S. Prevalence of low HDL-cholesterol levels and associated factors among Koreans. Circ. J. 2006;70:820–826. doi: 10.1253/circj.70.820.
    1. Young K.A., Maturu A., Lorenzo C., Langefeld C.D., Wagenknecht L.E., Chen Y.I., Taylor K.D., Rotter J.I., Norris J.M., Rasouli N. The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio as a predictor of insulin resistance, beta-cell function, and diabetes in Hispanics and African Americans. J. Diabetes Complicat. 2019;33:118–122. doi: 10.1016/j.jdiacomp.2018.10.018.
    1. Ko D.T., Alter D.A., Guo H., Koh M., Lau G., Austin P.C., Booth G.L., Hogg W., Jackevicius C.A., Lee D.S., et al. High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions: The CANHEART Study. J. Am. Coll. Cardiol. 2016;68:2073–2083. doi: 10.1016/j.jacc.2016.08.038.
    1. Ford E.S., Liu S. Glycemic index and serum high-density lipoprotein cholesterol concentration among us adults. Arch. Intern. Med. 2001;161:572–576. doi: 10.1001/archinte.161.4.572.
    1. Bentley A.R., Chen G., Shriner D., Doumatey A.P., Zhou J., Huang H., Mullikin J.C., Blakesley R.W., Hansen N.F., Bouffard G.G., et al. Gene-based sequencing identifies lipid-influencing variants with ethnicity-specific effects in African Americans. PLoS Genet. 2014;10:e1004190. doi: 10.1371/journal.pgen.1004190.
    1. Karthikeyan G., Teo K.K., Islam S., McQueen M.J., Pais P., Wang X., Sato H., Lang C.C., Sitthi-Amorn C., Pandey M.R., et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: An analysis from the INTERHEART Study. J. Am. Coll. Cardiol. 2009;53:244–253. doi: 10.1016/j.jacc.2008.09.041.
    1. Rysz J., Gluba-Brzozka A., Rysz-Gorzynska M., Franczyk B. The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease. Int. J. Mol. Sci. 2020;21:601. doi: 10.3390/ijms21020601.
    1. Walter M. Interrelationships among HDL metabolism, aging, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2009;29:1244–1250. doi: 10.1161/ATVBAHA.108.181438.
    1. Droomers M., Schrijvers C.T., Mackenbach J.P. Educational level and decreases in leisure time physical activity: Predictors from the longitudinal GLOBE study. J. Epidemiol. Community Health. 2001;55:562–568. doi: 10.1136/jech.55.8.562.
    1. Robinson S.M., Crozier S.R., Borland S.E., Hammond J., Barker D.J., Inskip H.M. Impact of educational attainment on the quality of young women’s diets. Eur. J. Clin. Nutr. 2004;58:1174–1180. doi: 10.1038/sj.ejcn.1601946.
    1. Schultz N.S., Chui K.K.H., Economos C.D., Lichtenstein A.H., Volpe S.L., Sacheck J.M. Impact of physical activity, diet quality and stress on cardiometabolic health in school employees. Prev. Med. Rep. 2020;20:101243. doi: 10.1016/j.pmedr.2020.101243.
    1. Kritz-Silverstein D., Barrett-Connor E., Wingard D.L. The relationship between multiparity and lipoprotein levels in older women. J. Clin. Epidemiol. 1992;45:761–767. doi: 10.1016/0895-4356(92)90053-P.
    1. Lv H., Yang X., Zhou Y., Wu J., Liu H., Wang Y., Pan Y., Xia Y. Parity and serum lipid levels: A cross-sectional study in chinese female adults. Sci. Rep. 2016;6:33831. doi: 10.1038/srep33831.
    1. Wang Q., Ferreira D.L.S., Nelson S.M., Sattar N., Ala-Korpela M., Lawlor D.A. Metabolic characterization of menopause: Cross-sectional and longitudinal evidence. BMC Med. 2018;16:17. doi: 10.1186/s12916-018-1008-8.
    1. Agongo G., Nonterah E.A., Debpuur C., Amenga-Etego L., Ali S., Oduro A., Crowther N.J., Ramsay M., as members of AWI-Gen and the H3Africa Consortium The burden of dyslipidaemia and factors associated with lipid levels among adults in rural northern Ghana: An AWI-Gen sub-study. PLoS ONE. 2018;13:e0206326. doi: 10.1371/journal.pone.0206326.
    1. Muennig P., Sohler N., Mahato B. Socioeconomic status as an independent predictor of physiological biomarkers of cardiovascular disease: Evidence from NHANES. Prev. Med. 2007;45:35–40. doi: 10.1016/j.ypmed.2007.04.005.
    1. King A.C., Haskell W.L., Young D.R., Oka R.K., Stefanick M.L. Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation. 1995;91:2596–2604. doi: 10.1161/01.CIR.91.10.2596.
    1. Gupta A.K., Ross E.A., Myers J.N., Kashyap M.L. Increased reverse cholesterol transport in athletes. Metabolism. 1993;42:684–690. doi: 10.1016/0026-0495(93)90233-E.
    1. Nakamura M., Yamamoto Y., Imaoka W., Kuroshima T., Toragai R., Ito Y., Kanda E., Schaefer E.J., Ai M. Relationships between Smoking Status, Cardiovascular Risk Factors, and Lipoproteins in a Large Japanese Population. J. Atheroscler. Thromb. 2020 doi: 10.5551/jat.56838.
    1. Jain R.B., Ducatman A. Associations between smoking and lipid/lipoprotein concentrations among US adults aged ≥ 20 years. J. Circ. Biomark. 2018;7:1849454418779310. doi: 10.1177/1849454418779310.
    1. van der Gaag M.S., van Tol A., Vermunt S.H., Scheek L.M., Schaafsma G., Hendriks H.F. Alcohol consumption stimulates early steps in reverse cholesterol transport. J. Lipid. Res. 2001;42:2077–2083. doi: 10.1016/S0022-2275(20)31537-6.
    1. Brien S.E., Ronksley P.E., Turner B.J., Mukamal K.J., Ghali W.A. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: Systematic review and meta-analysis of interventional studies. BMJ. 2011;342:d636. doi: 10.1136/bmj.d636.
    1. Traissac P., Pradeilles R., El Ati J., Aounallah-Skhiri H., Eymard-Duvernay S., Gartner A., Beji C., Bougatef S., Martin-Prevel Y., Kolsteren P., et al. Abdominal vs. overall obesity among women in a nutrition transition context: Geographic and socio-economic patterns of abdominal-only obesity in Tunisia. Popul. Health Metr. 2015;13:1. doi: 10.1186/s12963-015-0035-3.
    1. Woudberg N.J., Goedecke J.H., Blackhurst D., Frias M., James R., Opie L.H., Lecour S. Association between ethnicity and obesity with high-density lipoprotein (HDL) function and subclass distribution. Lipids Health Dis. 2016;15:92. doi: 10.1186/s12944-016-0257-9.
    1. Yu S., Guo X., Li G.X., Yang H., Zheng L., Sun Y. Lower or higher HDL-C levels are associated with cardiovascular events in the general population in rural China. Lipids Health Dis. 2020;19:152. doi: 10.1186/s12944-020-01331-6.
    1. Dalal J.J., Padmanabhan T.N., Jain P., Patil S., Vasnawala H., Gulati A. LIPITENSION: Interplay between dyslipidemia and hypertension. Indian J. Endocrinol. Metab. 2012;16:240–245. doi: 10.4103/2230-8210.93742.
    1. Opoku S., Gan Y., Fu W., Chen D., Addo-Yobo E., Trofimovitch D., Yue W., Yan F., Wang Z., Lu Z. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: Findings from the China National Stroke Screening and prevention project (CNSSPP) BMC Public Health. 2019;19:1500. doi: 10.1186/s12889-019-7827-5.
    1. Halperin R.O., Sesso H.D., Ma J., Buring J.E., Stampfer M.J., Gaziano J.M. Dyslipidemia and the risk of incident hypertension in men. Hypertension. 2006;47:45–50. doi: 10.1161/01.HYP.0000196306.42418.0e.
    1. Tohidi M., Hatami M., Hadaegh F., Azizi F. Triglycerides and triglycerides to high-density lipoprotein cholesterol ratio are strong predictors of incident hypertension in Middle Eastern women. J. Hum. Hypertens. 2012;26:525–532. doi: 10.1038/jhh.2011.70.
    1. Steyn K., Fourie J., Benade A.J., Rossouw J.E., Langenhoven M.L., Joubert G., Chalton D.O. Factors associated with high density lipoprotein cholesterol in a population with high high density lipoprotein cholesterol levels. Arteriosclerosis. 1989;9:390–397. doi: 10.1161/01.ATV.9.3.390.
    1. Freedman D.S., Srinivasan S.R., Shear C.L., Franklin F.A., Webber L.S., Berenson G.S. The relation of apolipoproteins A-I and B in children to parental myocardial infarction. N. Engl. J. Med. 1986;315:721–726. doi: 10.1056/NEJM198609183151202.
    1. Pirro M., Ricciuti B., Rader D.J., Catapano A.L., Sahebkar A., Banach M. High density lipoprotein cholesterol and cancer: Marker or causative? Prog. Lipid. Res. 2018;71:54–69. doi: 10.1016/j.plipres.2018.06.001.
    1. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J. Cardiovasc. Risk. 1996;3:213–219. doi: 10.1097/00043798-199604000-00014.
    1. Bolanos-Garcia V.M., Miguel R.N. On the structure and function of apolipoproteins: More than a family of lipid-binding proteins. Prog. Biophys. Mol. Biol. 2003;83:47–68. doi: 10.1016/S0079-6107(03)00028-2.
    1. Walldius G., Jungner I. The apoB/apoA-I ratio: A strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—A review of the evidence. J. Intern. Med. 2006;259:493–519. doi: 10.1111/j.1365-2796.2006.01643.x.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel